Abstract: Described is the sequential administration of first a Treg depleting antibody molecule selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti-body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. Described are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.
Type:
Grant
Filed:
July 26, 2018
Date of Patent:
September 20, 2022
Assignee:
CANCER RESEARCH TECHNOLOGY LIMITED
Inventors:
Björn Frendéus, Linda Mårtensson, Monika Semmrich, Ingrid Teige, Stephen Beers, Aymen Al-Shamkhani, Juliet Gray, Martin Glennie
Abstract: The present disclosure relates to anti-CD40 antibodies, such as humanized anti-CD40 antibodies, that may be used in various therapeutic, prophylactic and diagnostic methods. The antibodies generally block the ability of CD40 to bind CD154 and do so without activating the cell expressing CD40 (e.g., a B cell). The present antibodies or fragments thereof may be used to reduce complications associated with organ or tissue transplantation.
Abstract: Provided is an isolated antibody or antigen binding fragment thereof. The isolated antibody or antigen binding fragment thereof can be used to prepare a medicament for treating tumors.
Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
Type:
Grant
Filed:
June 11, 2021
Date of Patent:
September 13, 2022
Assignees:
GENMAB A/S, BIONTECH SE
Inventors:
Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Friederike Gieseke, Ugur Sahin
Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
Type:
Grant
Filed:
January 23, 2020
Date of Patent:
September 6, 2022
Assignee:
Alexion Pharmaceuticals, Inc.
Inventors:
Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini, Yi Wang
Abstract: The present invention relates to antagonistic antibodies specifically binding CD154, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
Type:
Grant
Filed:
April 21, 2020
Date of Patent:
August 23, 2022
Assignee:
Janssen Biotech, Inc.
Inventors:
Johan Fransson, Galina Obmolova, Anish Suri, Fang Teng, Alexey Teplyakov, Hong Zhou, Jocelyn Leu
Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
Type:
Grant
Filed:
September 12, 2019
Date of Patent:
August 9, 2022
Assignee:
Alexion Pharmaceuticals, Inc.
Inventors:
Russell P. Rother, Douglas L. Sheridan, Paul P. Tamburini, Yuchun Zhang
Abstract: The disclosure concerns antibodies that bind and antagonize CD40. These antibodies are particularly useful to inhibit immune responses and treat auto-immune diseases.
Abstract: Anti-CD40L antibodies and antigen binding fragments thereof, compositions comprising the antibodies or antigen binding fragments, Anti-CD40L antibodies with reduced effector function, and method of using same for treatment of CD40L-related diseases or disorders.
Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and/or human GITR receptor (GITR), including multispecific antibodies that bind, e.g., to OX40 and GITR, and compositions comprising such antibodies. The antibodies disclosed herein modulate OX40 and/or GITR activity e.g., enhance, activate, induce, reduce, deactivate, or inhibit OX40 and/or GITR activity. The present disclosure also provides methods for treating disorders, such as cancer, autoimmune diseases or disorders, or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and/or human GITR and modulates OX40 and/or GITR activity.
Type:
Grant
Filed:
May 9, 2019
Date of Patent:
June 14, 2022
Assignees:
AGENUS INC., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.
Inventors:
Nicholas S. Wilson, Jeremy D. Waight, Dennis J. Underwood, Ekaterina V. Breous-Nystrom, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Marc Van Dijk
Abstract: The invention provides antibodies or binding fragments thereof directed against citrulline-containing epitopes. The antibodies or binding fragments thereof of the invention can be used in therapy, for example in the treatment or prevention of Neutrophil Extracellular Trap (NET)-associated pathologies.
Type:
Grant
Filed:
July 6, 2021
Date of Patent:
May 31, 2022
Assignee:
CITRYLL B.V.
Inventors:
Jozef Maria Hendrik Raats, Renato Gerardus Silvano Chirivi, Johannes Wilhelmus Gerardus Van Rosmalen
Abstract: The present invention relates to an antibody against C5, and a method for preventing and treating complement-related diseases using the antibody, wherein the antibody against C5 is effectively usable in preventing and treating complement-related diseases by inhibiting complement activation.
Type:
Grant
Filed:
April 18, 2019
Date of Patent:
May 24, 2022
Assignee:
Seoul National University R&DB Foundation
Inventors:
Junho Chung, Hyori Kim, Hwa Kyoung Lee, Won Jun Yang
Abstract: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Chain swapping between natalizumab and IgG4 molecules acts to reduce the level of bivalent natalizumab present following administration of natalizumab, and thus to lower the activity of natalizumab in the patient. Differences in IgG4 levels across patients or within a single patient across time may change the pharmacokinetic profile of natalizumab. Patients with lower levels of IgG4 may experience higher nadir levels of natalizumab during a dosing period. Monitoring IgG4 and/or bivalent natalizumab levels, and determining a dose or dosage period based on the monitoring may improve the safety and/or efficacy of natalizumab therapy.
Abstract: The invention provides bispecific antibodies having one arm binding to a cancer associated antigen on a cancer cell, such as CD33, EGFR or PD-L1, and a second arm binding to a costimulatory molecule, such as OX40, CD40, GITR, ICOS or 4-1BB. Bridging by the bispecific antibody between cancer cells expressing the cancer associated antigen and immune cells expressing the costimulatory molecule results in clustering of the costimulatory molecules and selective activation of the immune cells at a location proximate to the cancer cells. Thus, the immune cells can exert an immunotherapeutic effect against the cancer cells with reduced toxicity to healthy tissue.
Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
Type:
Grant
Filed:
February 7, 2020
Date of Patent:
May 17, 2022
Assignees:
AGENUS INC., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.
Inventors:
Marc Van Dijk, Ekaterina V. Breous-Nystrom, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Hao Tang, David A. Savitsky, Nicholas S. Wilson
Abstract: The present technology aims at providing a novel type of drug. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF? and at least two ISVDs bind to IL-23. The present technology also provides nucleic acids, vectors and compositions.
Type:
Grant
Filed:
October 15, 2021
Date of Patent:
May 17, 2022
Assignees:
Ablynx N.V., Sanofi
Inventors:
Heidi Rommelaere, Christian Asbrand, Ann Brigé, Sigrid Cornelis, Eric Lorent
Abstract: A method of treating a Philadelphia chromosome-positive tumor in a subject comprises administering to the subject a therapeutic composition comprising an incubated combined mixture of (a) a first component comprising (i) Philadelphia chromosome-positive tumor lysate, (ii) plasmid encoding bcr/abl fusion protein, or (iii) bcr/abl fusion peptide; and (b) a second component comprising plasmacytoid dendritic cells expressing Toll-like receptor 9 and modified for stable expression of CD40 ligand or GM-CSF by a nucleotide sequence engineered into said plasmacytoid dendritic cells.
Abstract: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.
Abstract: The present invention relates to the field of inflammatory bowel disease. In one aspect, the present invention provides methods for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. In particular embodiments, the present invention provides a method for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of an agent that mobilizes CD34+ and/or CD133+ stem cells and a low dose of an immunosuppressive agent.